Balaxi Pharmaceuticals Limited (NSE:BALAXI)
India · Delayed Price · Currency is INR 24.04
+0.32 (1.35%)
Aug 19, 2026, 3:29 PM IST
Balaxi Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 2,801 | 2,702 | 2,926 | 2,413 | 3,364 | 2,794 |
Other Revenue | -0 | -0 | - | - | - | - |
| 2,801 | 2,702 | 2,926 | 2,413 | 3,364 | 2,794 | |
Revenue Growth | -5.90% | -7.65% | 21.25% | -28.28% | 20.42% | 20.77% |
Cost of Revenue | 1,554 | 1,518 | 1,659 | 1,289 | 2,072 | 1,980 |
Gross Profit | 1,247 | 1,184 | 1,266 | 1,124 | 1,293 | 814.24 |
Selling, General & Admin | 1,156 | 1,098 | 894.05 | 656.74 | 727.32 | 312.19 |
Other Operating Expenses | - | - | - | -0.11 | -0.26 | -0.3 |
Operating Expenses | 1,182 | 1,120 | 912.99 | 677.62 | 744.58 | 317.02 |
Operating Income | 65.03 | 63.75 | 353.21 | 446.44 | 548.12 | 497.22 |
Interest Expense | -36.3 | -39.04 | -29.35 | -16.77 | -5 | -1.42 |
Currency Exchange Gain (Loss) | 9.84 | 9.84 | -60.78 | -32.79 | 18.65 | 49.42 |
Other Non Operating Income (Expenses) | 25.18 | 17.33 | 23.61 | 6.21 | 7.46 | - |
EBT Excluding Unusual Items | 63.75 | 51.89 | 286.7 | 403.09 | 569.22 | 545.22 |
Other Unusual Items | 1.04 | 1.04 | - | -382.93 | - | - |
Pretax Income | 64.78 | 52.93 | 286.7 | 20.15 | 569.22 | 545.22 |
Income Tax Expense | 40.54 | 38.76 | 35.99 | 44.02 | 109.6 | 68.65 |
Net Income | 24.24 | 14.17 | 250.7 | -23.87 | 459.63 | 476.58 |
Net Income to Common | 24.24 | 14.17 | 250.7 | -23.87 | 459.63 | 476.58 |
Net Income Growth | -87.16% | -94.35% | - | - | -3.56% | 24.96% |
Shares Outstanding (Basic) | 54 | 55 | 55 | 51 | 50 | 50 |
Shares Outstanding (Diluted) | 54 | 55 | 55 | 51 | 51 | 50 |
Shares Change | - | - | 7.26% | 1.69% | 1.23% | - |
EPS (Basic) | 0.45 | 0.26 | 4.54 | -0.46 | 9.16 | 9.53 |
EPS (Diluted) | 0.45 | 0.26 | 4.54 | -0.46 | 9.08 | 9.53 |
EPS Growth | - | -94.35% | - | - | -4.74% | 24.96% |
Free Cash Flow | - | -414.25 | -561.23 | 41.74 | -69.83 | 288.23 |
Free Cash Flow Per Share | - | -7.50 | -10.17 | 0.81 | -1.38 | 5.76 |
Dividend Per Share | - | - | - | - | - | 0.100 |
Dividend Growth | - | - | - | - | - | - |
Gross Margin | 44.51% | 43.81% | 43.28% | 46.58% | 38.42% | 29.14% |
Operating Margin | 2.32% | 2.36% | 12.07% | 18.50% | 16.29% | 17.80% |
Profit Margin | 0.86% | 0.52% | 8.57% | -0.99% | 13.66% | 17.06% |
Free Cash Flow Margin | - | -15.33% | -19.18% | 1.73% | -2.08% | 10.32% |
EBITDA | 84.9 | 83.43 | 372.15 | 467.42 | 565.64 | 502.34 |
EBITDA Margin | 3.03% | 3.09% | 12.72% | 19.37% | 16.81% | 17.98% |
D&A For EBITDA | 19.87 | 19.68 | 18.95 | 20.98 | 17.53 | 5.12 |
EBIT | 65.03 | 63.75 | 353.21 | 446.44 | 548.12 | 497.22 |
EBIT Margin | 2.32% | 2.36% | 12.07% | 18.50% | 16.29% | 17.80% |
Effective Tax Rate | 62.58% | 73.23% | 12.55% | 218.44% | 19.25% | 12.59% |
Revenue as Reported | 2,837 | 2,730 | 2,888 | 2,386 | 3,391 | 2,844 |
Advertising Expenses | - | 284.8 | 6.41 | 6.55 | 8.41 | 10.21 |